Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,045 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011.
Antinori A, Marcotullio S, Ammassari A, Andreoni M, Angarano G, Armignacco O, Carosi G, Cinque P, d'Arminio Monforte A, Di Perri G, Ensoli B, Floridia M, Galli M, Mastroianni C, Matteelli A, Mazzotta F, Moroni M, Pal G, Puoti M, Puro V, Rizzardini G, Sagnelli E, Vella S, Vullo V, Lazzarin A; Italian HIV Guidelines Working Group. Antinori A, et al. Among authors: galli m. New Microbiol. 2012 Apr;35(2):113-59. Epub 2012 Mar 31. New Microbiol. 2012. PMID: 22707127 Free article. No abstract available.
Clinical and immunological aspects of HIV infection in drug addicts.
Galli M, Lazzarin A, Saracco A, Balotta C, Castagna A, Negri C, Ridolfo AL, Uberti-Foppa C, Corbellino M, Moroni M. Galli M, et al. Clin Immunol Immunopathol. 1989 Jan;50(1 Pt 2):S166-76. doi: 10.1016/0090-1229(89)90124-4. Clin Immunol Immunopathol. 1989. PMID: 2562942
Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment.
Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, Molteni C, Trabattoni D, Fossati S, Clerici M, Galli M, Moroni M, Franzetti F, Gori A. Marchetti G, et al. Among authors: galli m. J Infect Dis. 2002 Sep 1;186(5):606-16. doi: 10.1086/342479. Epub 2002 Aug 9. J Infect Dis. 2002. PMID: 12195347 Clinical Trial.
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.
Galli M, Cozzi-Lepri A, Ridolfo AL, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Vaccarezza M, Vullo V, Cargnel A, Minoli L, Coronado O, Giacometti A, Antinori A, Antonucci G, D'Arminio Monforte A, Moroni M; LipoICoNa Study. Galli M, et al. Arch Intern Med. 2002 Dec 9-23;162(22):2621-8. doi: 10.1001/archinte.162.22.2621. Arch Intern Med. 2002. PMID: 12456235
Relationship between HAART adherence and adipose tissue alterations.
Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo AL, Mazzotta F, Wu AW, d'Arminio Monforte A, Galli M; AdICoNA Study Group. LipoICoNA Study Group. Ammassari A, et al. Among authors: galli m. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S140-4. doi: 10.1097/00126334-200212153-00011. J Acquir Immune Defic Syndr. 2002. PMID: 12562038
2,045 results